D-dimer: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Howard C. Berkowitz
No edit summary
Line 6: Line 6:
==Using D-dimer to determine duration of anticoagulation treatment==
==Using D-dimer to determine duration of anticoagulation treatment==
An abnormal D-dimer level at the end of treatment might signal the need for continued [[anticoagulation]] with [[warfarin]] among patients with [[embolism and thrombosis]] such as a first unprovoked [[pulmonary embolism]]. If the D-dimer is abnormal, anticoaguation should be continued, if the D-dimer is normal, the duration of treatment is uncertain.<ref name="pmid17065639">{{cite journal |author=Palareti G, Cosmi B, Legnani C, ''et al'' |title=D-dimer testing to determine the duration of anticoagulation therapy |journal=N. Engl. J. Med. |volume=355 |issue=17 |pages=1780-9 |year=2006 |pmid=17065639 |doi=10.1056/NEJMoa054444}}</ref> In an observation study that collected the D-dimer before stopping anticoagulation, the D-dimer was not as predictive.<ref>Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. [http://www.cmaj.ca/cgi/content/full/179/5/417 Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy]. CMAJ. 2008 Aug 26;179(5):417-426.</ref>
An abnormal D-dimer level at the end of treatment might signal the need for continued [[anticoagulation]] with [[warfarin]] among patients with [[embolism and thrombosis]] such as a first unprovoked [[pulmonary embolism]]. If the D-dimer is abnormal, anticoaguation should be continued, if the D-dimer is normal, the duration of treatment is uncertain.<ref name="pmid17065639">{{cite journal |author=Palareti G, Cosmi B, Legnani C, ''et al'' |title=D-dimer testing to determine the duration of anticoagulation therapy |journal=N. Engl. J. Med. |volume=355 |issue=17 |pages=1780-9 |year=2006 |pmid=17065639 |doi=10.1056/NEJMoa054444}}</ref> In an observation study that collected the D-dimer before stopping anticoagulation, the D-dimer was not as predictive.<ref>Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. [http://www.cmaj.ca/cgi/content/full/179/5/417 Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy]. CMAJ. 2008 Aug 26;179(5):417-426.</ref>
 
==Screening for deep venous thrombosis==
==References==
==References==
<references/>
<references/>

Revision as of 01:03, 22 June 2009

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In medicine, D-dimer is a fibrin degradation product after coagulation.

Immunologic tests for d-dimer are generally use immunoassays such as enzyme-linked immunosorbent assay or serologic tests such as agglutination tests. Immunoassays tend to be more sensitive while agglutination tests (such as the SimpliRED) tend to be more specific.[1]

Using D-dimer to determine duration of anticoagulation treatment

An abnormal D-dimer level at the end of treatment might signal the need for continued anticoagulation with warfarin among patients with embolism and thrombosis such as a first unprovoked pulmonary embolism. If the D-dimer is abnormal, anticoaguation should be continued, if the D-dimer is normal, the duration of treatment is uncertain.[2] In an observation study that collected the D-dimer before stopping anticoagulation, the D-dimer was not as predictive.[3]

Screening for deep venous thrombosis

References

  1. Stein PD, Hull RD, Patel KC, et al. (April 2004). "D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review". Ann. Intern. Med. 140 (8): 589–602. PMID 15096330[e]
  2. Palareti G, Cosmi B, Legnani C, et al (2006). "D-dimer testing to determine the duration of anticoagulation therapy". N. Engl. J. Med. 355 (17): 1780-9. DOI:10.1056/NEJMoa054444. PMID 17065639. Research Blogging.
  3. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008 Aug 26;179(5):417-426.